Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America

Lung Cancer

Volumn 49, Issue 2, 2005, Pages 225-231

  Ho, Cheryl ^a   Murray, Nevin ^a   Laskin, Janessa ^a   Melosky, Barbara ^a   Anderson, Helen ^a   Bebb, Gwyn ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Adenocarcinoma; Asian; EGFR; Gefitinib; Non small cell lung cancer; Predictive factors

Indexed keywords

GEFITINIB;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASIA; CANCER GROWTH; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG RESPONSE; ETHNOLOGY; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER TOXICITY; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; PRIORITY JOURNAL; RADIOLOGY; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NORTH AMERICA; PREDICTIVE VALUE OF TESTS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 22044438962     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.02.011     Document Type: Article

References (37)

1. E. Raymond, S. Faivre, and J.P. Armand Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 Suppl. 1 2000 15 23 [discussion 41-2]
2. C.A. Ritter, and C.L. Arteaga The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors Semin Oncol 30 1 Suppl. 1 2003 3 11
3. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl. 4 2001 S9 S15
4. F.R. Hirsch Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 20 2003 3798 3807
5. J. Brabender Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival Clin Cancer Res 7 7 2001 1850 1855
6. Y. Ohsaki Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression Oncol Rep 7 3 2000 603 607
7. C.L. Arteaga, and D.H. Johnson Tyrosine kinase inhibitors-ZD1839 (Iressa) Curr Opin Oncol 13 6 2001 491 498
8. K. Nakagawa Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors Ann Oncol 14 6 2003 922 930
9. J. Baselga Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 20 21 2002 4292 4302
10. R.S. Herbst Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial J Clin Oncol 20 18 2002 3815 3825
11. M. Ranson ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 9 2002 2240 2250
12. M. Fukuoka Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 12 2003 2237 2246
13. M.G. Kris Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 16 2003 2149 2158
14. Astrazeneca, http://www.astrazeneca.com/productbrowse/5_84.aspx.
15. P.A. Janne Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study Lung Cancer 44 2 2004 221 230
16. H. West Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): southwest oncology group (SWOG) study S0126 J Clin Oncol 22 Suppl. 14 2004 7014 [meeting abstracts]
17. R.B. Reiling Clinical benefit with compassionate use gefitinib in a subset of non-small-cell lung cancer (NSCLC) patients with the bronchoalveolar (BAC) subtype treated during an expanded access program (EAP) J Clin Oncol 22 Suppl. 14 2004 7087 [meeting abstracts]
18. V.A. Miller Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 6 2004 1103 1109
19. L.R. Bailey Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy J Clin Oncol 22 Suppl. 14 2004 7013 [meeting abstracts]
20. W. Pao Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib J Clin Oncol 22 Suppl. 14 2004 7025 [meeting abstracts]
21. T.J. Lynch Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 21 2004 2129 2139
22. J.G. Paez EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 2004 1497 1500
23. S. Green, and G.R. Weiss Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria Invest New Drugs 10 4 1992 239 253
24. CTEP, N., http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf ; 1999.
25. N.T. Shah Bronchioalveolar histology and smoking history predict response to gefitinib Proc ASCO 22 2003 628
26. V.A. Miller Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: sub-group analysis of TRIBUTE J Clin Oncol 22 Suppl. 14 2004 7061 [meeting abstracts]
27. V.A. Miller The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): preliminary results of a phase II trial Proc ASCO 22 2003 619
28. G.M. Clark Rash severity is predictive of increased survival with erlotinib HCl Proc ASCO 22 2003 196
29. K. Goto Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer J Clin Oncol 22 Suppl. 14 2004 7098 [meeting abstracts]
30. N. Katakami A retrospective analysis of the outcome of patients (pts) in advanced recurrent adenocarcinoma of the lung who have received gefitinib after treatment of platinum-based regimen Proc ASCO 22 2003 666
31. M.G. Mainwaring Gefitinib (ZD1839) in the treatment of patients with advanced refractory non-small cell lung cancer (NSCLC): 250 patients treated at the Sarah Cannon Cancer Center Proc ASCO 22 2003 690
32. A.G. Pallis ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program Lung Cancer 40 3 2003 301 307
33. M. Parton Gefitinib in patients with non-small cell lung cancer (NSCLC): the Royal Marsden experience J Clin Oncol 22 Suppl. 14 2004 7099 [meeting abstracts]
34. G.R. Simon Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution Cancer Control 10 5 2003 388 395
35. L.N. Kolonel, D. Altshuler, and B.E. Henderson The multiethnic cohort study: exploring genes, lifestyle and cancer risk Nat Rev Cancer 4 7 2004 519 527
36. M.C. Liu, A. Hai, and A.T. Huang Cancer epidemiology in the Far East - contrast with the United States Oncology (Huntingt) 7 6 1993 99 110 [discussion 133-4]
37. M. McCredie, S. Williams, and M. Coates Cancer mortality in migrants from the British Isles and continental Europe to New South Wales, Australia Int J Cancer 83 2 1999 179 185